IN BRIEF: ImmuPharma forecasts "year of delivery" in 2026
ImmuPharma PLC - London-based specialist drug discovery and development company - Chair Tim McCarthy produces open letter to shareholders, noting that resolutions relating to the proposed GBP6 million Lanstead subscription and GBP468,000 WRAP retail offer were approved at the general meeting. Says the fundraise "significantly strengthens our balance sheet and provides the capital required to advance our key strategic priorities." McCarthy adds that ImmuPharma's primary focus remains securing a value-enhancing partnering agreement for lead auto-immune technology platform, P140, this year, as recent progress "continues to reinforce both [its] scientific rationale and commercial positioning," and management is "actively engaged in progressing discussions toward this objective". ImmuPharma is also investing in its "second key asset", type 1 diabetes treatment Kapiglucagon. Says the structure of the Lanstead subscription provides a mechanism to potentially benefit from future share price performance, with an 8 pence benchmark acting as the reference point for returns, meaning that progress on P140 and Kapiglucagon could "support value creation over the period of the [sharing] agreement." Read More